You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
The US Food and Drug Administration has issued an Emergency Use Authorization for Abbott's antigen test for SARS-CoV-2.
According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.
Significant revenue from molecular and rapid diagnostic testing for SARS-CoV-2 offset declines in core lab volumes.
The firm's various COVID-19 molecular test offerings offset declines in core laboratory and point-of-care segments.
News items for the week of June 8, 2020.
Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.